Divi's Laboratories Limited vs Neuland Laboratories Limited
An objective side-by-side of DIVISLAB and NEULANDLAB, both in Pharmaceuticals - Indian - Bulk Drugs: valuation, profitability, growth, balance sheet, ownership and share-price performance. Where one number is clearly better on its own terms (lower P/E, higher ROE), it is shaded. That is a description, not a recommendation.
Prices as of 2026-11-05 close
Latest results: DIVISLAB Jun 2026 · NEULANDLAB Sep 2026
At a glance
- Divi's Laboratories Limited is the larger company by market value, about 10.6 times the size of Neuland Laboratories Limited.
- On trailing earnings, Neuland Laboratories Limited trades at the lower P/E (56.0 against 92.0).
- Neuland Laboratories Limited earns the higher return on equity (22.3% against 17.5%).
- Over three years Neuland Laboratories Limited has grown profits faster (30% a year against 13%).
- Over the past year the share prices returned +52.4% (DIVISLAB) and +22.4% (NEULANDLAB).
| Metric | Divi's Laboratories DIVISLAB |
Neuland Laboratories NEULANDLAB |
|---|---|---|
| Size and price | ||
| Market cap | ₹269,198 Cr | ₹25,381 Cr |
| Share price | ₹10,140.50 | ₹19,783.00 |
| Valuation | ||
| P/E | 92.03 | 55.99 |
| P/B | 16.06 | 12.50 |
| EV/EBITDA | 67.86 | 36.52 |
| PEG | 7.08 | 1.87 |
| Dividend yield | 0.3% | 0.2% |
| Profitability | ||
| ROE | 17.5% | 22.3% |
| ROCE | 22.0% | 27.0% |
| Operating margin | 35.3% | 30.5% |
| Sales (TTM) | ₹11,230 Cr | ₹2,307 Cr |
| Net profit (TTM) | ₹2,925 Cr | ₹453 Cr |
| Growth | ||
| Latest quarter sales YoY | +27.8% | -12.6% |
| Latest quarter profit YoY | +65.5% | -46.7% |
| Sales CAGR 3Y | +11.0% | +19.0% |
| Profit CAGR 3Y | +13.0% | +30.0% |
| Sales CAGR 5Y | +9.0% | +17.0% |
| Profit CAGR 5Y | +6.0% | +39.0% |
| Financial strength | ||
| Debt/Equity | 0.00 | 0.17 |
| Interest cover | 129.48 | 20.14 |
| Ownership | ||
| Promoter holding | 51.9% | 32.3% |
| Promoter change (4 qtrs) | +0.00 pp | -0.38 pp |
| Price performance | ||
| Return 1M | +6.18% | -9.69% |
| Return 3M | +20.89% | -0.87% |
| Return 1Y | +52.37% | +22.43% |
| Return YTD | +58.63% | +30.37% |
| Technical condition | ||
| Technical score | 94 | 46 |
| RS rating (1-99) | 92.00 | 82.00 |
| % vs 200-DMA | +37.34% | +13.05% |
| RSI (14) | 70.55 | 44.37 |
| % from 52-week high | -0.18% | -18.34% |
